Vaxil Granted First U.S. Patent for Its Cancer Immunotherapy Antibody Platform
NESS-ZIONA, ISRAEL--(Marketwired - March 01, 2018) - VAXIL BIO LTD. (TSX VENTURE: VXL), an innovative Israeli cancer research company focused on immunotherapy, is pleased to announce that it has successfully obtained a U.S. Patent for its Signal Peptide …